PDGFRA and soft tissue sarcoma: Moreover, a trial in participants with soft tissue sarcoma (STS) wherein platelet-derived growth factor (PDGF)/PDGF receptor (PDGFR) signaling plays a significant role, reported a clinical benefit in participants treated with olaratumab (PDGFRα monoclonal antibody) [10] in combination with chemotherapy [11].